Use of retinoic acid receptor (rar) agonists forreversin g, preventing, or delaying calcification of aorticvalve

Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve - a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.

Keywords: Calcification
Patent Application number: 19 306 256.9

Reference:

BIO17543-T1

Business Developper
contact
Aymeric Empereur
Aymeric Empereur
Business Developer
Patent filling date: 2019-10-02

You might also be interested in